title: Dose-Intensified Chemotherapy for Breast Cancer: Present and Future Prospects.
abstract: With the trend to maximize chemotherapy in breast cancer, the use of peripheral blood stem cells in addition to hematopoietic growth factors to alleviate myelosuppression caused by dose-intensified chemotherapy has been shown to be beneficial. In treatment of metastatic breast cancer, response rates and complete response rates as high as 100%and nearly 80%, respectively, have been reported. Such treatments have shown even greater promise in an adjuvant setting for high-risk breast cancer. High-dose chemotherapy studies, however, involve highly-selected patient populations who are generally compared with unselected patients, and controversy still surrounds the question of whether it is substantially superior to conventional-dose chemotherapy. There are now more than sufficient data to justify ongoing randomized trials, and the most important overall recommedation is to encourage patients to participate in these clinical trials.
authors.affiliation: Department of Geneal Surgery, Tokai University School of Medicine, Bohseidai, Isehara 259-11, Japan.
authors.initials: T
authors.lastname: Tajima
authors.initials: Si
authors.lastname: Kuge
authors.initials: Y
authors.lastname: Suzuki
authors.initials: A
authors.lastname: Okumura
authors.initials: M
authors.lastname: Ohta
authors.initials: Y
authors.lastname: Tokuda
authors.initials: M
authors.lastname: Kubota